Sub-Journal of "Science": Borrowing the successful experience of hepatitis B vaccine, scientists develop a new type of new crown vaccine

In a research paper published online recently in Science Immunology, a sub-Journal of "Science", a multidisciplinary research team brought a new candidate for the new crown vaccine

The researchers emphasized in the paper that the new crown vaccine being developed is suitable for large-scale production and will help meet the demand for vaccination around the world, so that more people have the opportunity to be protected

In the history of humans using vaccines to prevent viral infections, the hepatitis B vaccine developed using yeast cells is an important milestone, saving countless lives

Using this experience, researchers from Emory University, Infectious Disease Research Institute (IDRI), 3M and Baylor College of Medicine (Baylor College of Medicine) collaborated to develop this new crown vaccine

The researchers cloned and expressed the new coronavirus-specific surface protein in the yeast expression system, the receptor binding domain of the spike protein, as an immune antigen

In monkey experiments, the new crown vaccine produced with yeast has achieved significant protective effects

In addition, the researchers also compared the difference between using 3M-052-alum adjuvant and traditional alum adjuvant

▲The animal received 3 doses of recombinant protein vaccine.

Researchers believe that the enhanced T cell response seen in animal experiments also means that this vaccine is likely to provide a wide range of protection for humans, especially against the emerging new crown mutation

Professor Maria Elena Bottazzi, one of the co-corresponding authors of the study and a vaccine development expert at Baylor College of Medicine, concluded: “Our results show that the use of yeast expression platforms to produce RBD recombinant proteins is expected to meet the vaccination needs around the world; we are very pleased Seeing that this candidate vaccine has the advantage of balancing antibody and CD8+ T cell responses, which is not available in other protein-based vaccine methods before

Reference materials:

[1] Maria Pino et al.

[2] New COVID-19 vaccine candidate provides effective option for low- to mid-income countries.